FDA warned telehealth site inspire.clinic that claims its compounded semaglutide and tirzepatide are similar to Ozempic or Mounjaro misbrand the drugs.
What happened
FDA reviewed the website https://www.inspire.clinic in August 2025 and observed that it offers compounded semaglutide and tirzepatide drug products. FDA said website claims such as “similar to Ozempic,” “similar to Mounjaro,” and “comparable to Ozempic” are false or misleading because compounded drugs are not FDA-approved.
What FDA found
The website claimed compounded semaglutide was “similar to Ozempic” and compounded tirzepatide was “similar to Mounjaro,” implying they are the same as FDA-approved drugs when compounded drugs are not FDA-approved.
FDCA §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The website claim that “5 mg of semaglutide [is] comparable to Ozempic” is false or misleading for the same reason.
FDCA §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]Because the labeling and advertising were false or misleading, FDA says the compounded semaglutide and tirzepatide products are misbranded.
FDCA §§ 502(a), 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]FDA says introducing or delivering these misbranded drugs into interstate commerce is a prohibited act.
FDCA § 301(a) [21 U.S.C. § 331(a)]FDA also says receiving, delivering, or offering delivery of misbranded drugs in interstate commerce is prohibited.
FDCA § 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days, provide a written response to CDER’s Office of Compounding Quality and Compliance describing steps taken to correct the violations and prevent recurrence, with supporting documents. FDA also says to take immediate action, including ceasing the misleading claims.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies and their marketing partners
- regulatory teams reviewing drug promotional claims
This is a summary. Read the original letter on fda.gov.